The IFM team sets up a three-peat as Novartis funds cGAS/STING program — with $840M option to buy
First there was Bristol-Myers Squibb’s $2.3 billion-plus deal with IFM — $300 million up front — to grab preclinical small molecules to activate NLRP3 and STING in fighting cancer. That was 2 years ago.
Then Novartis’ translational team under Jay Bradner jumped in and grabbed the flip side of that coin, paying the IFM crew $310 million upfront in a $1.6 billion bid to demonstrate what NLRP3 can do as an anti-inflammatory. That work — held in a subsidiary called IFM Tre — had just begun human studies 5 months ago.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.